Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Gagne, N. Choudhry, A. Kesselheim, J. Polinski, D. Hutchins, O. Matlin, T. Brennan, J. Avorn, W. Shrank (2014)
Comparative Effectiveness of Generic and Brand-Name Statins on Patient OutcomesAnnals of Internal Medicine, 161
J. Yeh, J. Franklin, J. Avorn, J. Landon, A. Kesselheim (2016)
Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.JAMA internal medicine, 176 6
F. Greaves, A. Jha (2014)
Quality and the curate's eggBMJ Quality & Safety, 23
(2016)
Now there’s proof: docs who get company cash tend to prescribe more brand-name meds. https://www.propublica.org /article/doctors-who-take-company-cash-tend-to-prescribe-more-brand-name -drugs
Jing Luo, J. Seeger, M. Donneyong, J. Gagne, J. Avorn, A. Kesselheim (2016)
Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.JAMA internal medicine, 176 9
J. Larosa, S. Grundy, D. Waters, C. Shear, P. Barter, J. Fruchart, A. Gotto, H. Greten, J. Kastelein, J. Shepherd, N. Wenger (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.The New England journal of medicine, 352 14
C. DeJong, Thomas Aguilar, Chien-Wen Tseng, Grace Lin, W. Boscardin, R. Dudley (2016)
Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.JAMA internal medicine, 176 8
(2011)
Senators probe efforts to beat back generic Lipitor
S. Murphy, C. Cannon, S. Wiviott, C. Mccabe, E. Braunwald (2009)
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial InfarctionJournal of the American College of Cardiology, 54 25
piration, Lipitor was actually cheaper during 2011 than its generic equivalent. Payments to Physicians, Prescribing Rates, Physicians might choose atorvastatin over other statins, and More Appropriate Conclusions as studies have shown it may be superior in the settings of myo- To the Editor In a study in a recent issue of JAMA Internal cardial infarction and cerebrovascular events and for overall Medicine, Yeh et al draw a broad conclusion that there is a posi- 3-5 1 lipid reduction. Since Yeh et al used a claims database, they tive linear relationship between pharmaceutical industry pay- had no information on why clinicians chose a particular statin ments to physicians and higher rates of prescribing brand name and not another. The frequent use of atorvastatin in 2011 could statins. The authors, however, acknowledge that there is no such be based on the studies indicating increased efficacy over other relationship over the range of $0 to $2000 per physician during available statins. the study period. The article does not include the number of phy- 1 It may not have been possible for Yeh et al to answer the sicians in this group, but because the median payment for the key question they set
JAMA Internal Medicine – American Medical Association
Published: Oct 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.